Home/Pipeline/NRM-823

NRM-823

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Normunity

About Normunity

Normunity is a private, preclinical-to-clinical stage biotech founded in 2021 and based in New Haven, CT, focused on oncology and immunology. The company's core innovation is its discovery platform, born from a deep, ongoing partnership with the Lieping Chen lab at Yale, which identifies novel 'Immuno-smart' targets that are both tumor-specific and central to immune evasion. This approach has yielded a pipeline of biologic therapies, led by NRM-823, a T cell engager that has recently entered clinical development. Led by CEO Rachel Humphrey, a veteran developer of major cancer immunotherapies, Normunity aims to create a new generation of medicines that free normal immunity to defeat a broad array of solid tumors.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed